BCAL Diagnostics Limited (AU:BDX) has released an update.
BCAL Diagnostics Limited has announced the issuance of 43 million shares at $0.10 each to professional and sophisticated investors under specific Australian Corporations Act provisions without public disclosure. The company confirms compliance with all necessary legal requirements and asserts that no critical undisclosed information exists at the time of the notice. BCAL, known for its innovative blood test for breast cancer detection, continues to focus on early diagnosis and improved patient outcomes.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.
